Leslie Dan Faculty of Pharmacy, University of Toronto, Canada; Astellas Pharma Canada, Inc, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Canada; WHO Collaborating Centre for Governance, Transparency and Accountability in the Pharmaceutical Sector, University of Toronto, Canada.
Health Policy. 2022 Aug;126(8):795-801. doi: 10.1016/j.healthpol.2022.05.003. Epub 2022 May 13.
The Government of Canada plans to implement new controls on the prices of patented drugs sold in Canada. The literature indicates that such controls delay drug launches. The Government of Canada, in its cost benefit analysis of the proposed regulatory changes, claims that they do not. To examine this claim, we use recent OECD country level data to estimate regression models of drug launches. These estimates suggest that higher drug list prices increase the number of launches of new medicines; the estimates are larger in the short term than in the longer term. If our estimates have a causal interpretation, then, consistent with the extant literature, drug list price reductions delay availability of new medicines in the OECD countries. We explore the implications of these findings.
加拿大政府计划对在加拿大销售的专利药品价格实施新的控制。文献表明，这种控制会延迟药品的推出。加拿大政府在其对拟议监管改革的成本效益分析中声称并非如此。为了检验这一说法，我们使用最近的经合组织国家层面的数据来估计药品推出的回归模型。这些估计表明，较高的药品目录价格会增加新药品的推出数量；短期的估计值大于长期的估计值。如果我们的估计具有因果关系的解释，那么，与现有文献一致的是，药品目录价格的降低会延迟经合组织国家新药品的供应。我们探讨了这些发现的含义。
